| Document |
Document Title |
|
WO/2019/236957A1 |
Provided herein are small molecule inhibitors of Polycomb Repressive Complex 1 (PRC1) activity, and methods of use thereof for the treatment of disease, including leukemia and other cancers, as well as other diseases dependent on the act...
|
|
WO/2019/229239A1 |
A compound of formula (I) wherein: M is selected from Mo or W; X is selected from O or NR5; R1 and R2 are independently selected from H, C1-6 alkyl, and aryl; C1-6 alkyl and aryl optionally being substituted with one or more of C1-6 alky...
|
|
WO/2019/226991A1 |
Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided. Uses of such compounds for modulating androgen receptor activity, imag...
|
|
WO/2019/220293A1 |
Described herein is a perfluorinated aminoolefin compound of general formula (I): CFY=CXN(Rf)CF2Rf' where: (a) Rf and Rf' are (i) independently selected from a linear or branched perfluoroalkyl group having 1-8 carbon atoms, optionally c...
|
|
WO/2019/221122A1 |
The present invention addresses the problem of providing a compound having a β-lactamase inhibitory activity. The problem is solved by a compound which is represented by general formula (1) that represents a compound in which a specific...
|
|
WO/2019/221641A1 |
The invention relates to medical chemistry, specifically to new biologically active compounds - amide derivatives of prostaglandin F2 alpha. Said compounds have low cytotoxicity and are able to stimulate the formation of endogenous nitri...
|
|
WO/2019/220125A1 |
This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections.More specifically, the com...
|
|
WO/2019/222105A1 |
A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I: R20 –(Z)b–(Y)c–(R21)a–(X)d–R22–R23 wherein R20 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted...
|
|
WO/2019/217890A1 |
Pharmaceutical compositions of the invention comprise functionalized lactam derivatives of formula (I) having a disease-modifying action in the treatment of diseases associated with dysregulation of 5- hydroxytryptamine receptor 7 activi...
|
|
WO/2019/215022A1 |
The présent invention is related to a method for nucleating crystals from a solution comprising the steps of: injecting in a first capillary (1) tube an under saturated solution comprising a solvent and a soluble compound to be crystall...
|
|
WO/2019/213106A1 |
The present disclosure relates to solid state forms of Idasanutlin and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
|
|
WO/2019/212357A1 |
Disclosed are compounds comprising a linker for increasing trans-cyclooctene stability. The linker of the invention is a three-arm linker. In some embodiments, one arm of the linker is attached to a trans-cyclooctene moiety, another arm ...
|
|
WO/2019/206834A1 |
The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or ...
|
|
WO/2019/204505A2 |
Provided herein are compounds comprising a vinyl sulfonamide moiety. Also provided herein are pharmaceutical compositions comprising such compounds, and methods of using such compounds and pharmaceutical compositions for inhibiting the p...
|
|
WO/2019/197682A1 |
The invention relates to pharmaceutical combination products comprising an HDAC inhibitor, e.g. (E)-N-(2-amino-phenyl)-3-{1-[4-(1-methyl-1H-pyrazol-4-yl)-be
nzenesulfonyl]-1H-pyrrol-3-yl}- acrylamide as well as salts and or solvents ther...
|
|
WO/2019/200202A1 |
Disclosed are small molecule antagonists of α4β7 integrin, and methods of using them to treat a number of specific diseases or conditions.
|
|
WO/2019/196835A1 |
Provided in the present invention are a proline derivative, a preparation method therefor and an application thereof in preparing a drug for treating cardiovascular and cerebrovascular disease. The structure of the proline derivative is ...
|
|
WO/2019/196915A1 |
The present invention relates to a method for preparing a pyrroloaminopyridazinone compound and intermediates thereof. Specifically relating to a method for preparing the compound of formula (I), the target product being prepared by mean...
|
|
WO/2019/196898A1 |
Provided in the present invention are a 2-(2,2-diarylethyl)-cyclic amine derivative or salt, the synthesis thereof, and an application and composition thereof. Biological activity tests show that the 2-(2,2-diarylethyl)-cyclic amine deri...
|
|
WO/2019/193068A1 |
The present invention relates to a process for the synthesis of a carbon labeled organic compound containing a carbon labeled carboxyl group. The present invention also concerns the use of carbon labeled organic compounds containing a ca...
|
|
WO/2019/193159A1 |
The present invention relates to bumetanide derivatives of formula (I) as well as pharmaceutical compositions comprising these compounds for use in the treatment or prevention of diseases/disorders involving Na+- K+- 2CI- - cotransporter...
|
|
WO/2019/193062A1 |
The invention discloses compounds of Formula (I) wherein R1, R2, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharm...
|
|
WO/2019/192912A1 |
There is provided a synthesis of [18F]SFB (N-succinimidyl 4-[18F]fluorobenzoate) using a one-step reaction procedure without generating radioactive waste gases. [18F]SFB is useful as a reagent for labeling of low- and high-molecular weig...
|
|
WO/2019/193951A1 |
This organic solvent purification system, that separates and purifies an organic solvent from a mixed liquid containing an organic solvent such as N-methyl-2-pyrrolidone and water, is provided with: a pervaporation apparatus which is pro...
|
|
WO/2019/189274A1 |
The purpose of the present invention is to provide a tetraalkyl ammonium nitrite production method that makes it possible to achieve efficient production and/or makes it possible to improve the purity of a target substance. A tetraalkyl ...
|
|
WO/2019/189766A1 |
[Problem] To provide: a compound which is a muscarinic M3 receptor positive allosteric modulator, in particular, a compound having a structure represented by formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof,...
|
|
WO/2019/186522A1 |
The present invention generally relates to an improved process for preparation of lopinavir and its intermediates through formation of tartrate salt of compound of Formula (III).
|
|
WO/2019/185016A1 |
A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrica...
|
|
WO/2019/181984A1 |
Branched monodispersed polyethylene glycol represented by formula (1). (X1 is a functional group that reacts with a functional group present in a biofunctional molecule to form a covalent bond; n is an integer of 4-50 and represents the ...
|
|
WO/2019/183589A1 |
The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.
|
|
WO/2019/178699A1 |
The present description relates to glycoconjugates, glycoconjugate immunogens and glycoconjugate vaccines comprising carbohydrate antigens coupled to immunogenic carrier proteins, or materials used for detection and screening of resultin...
|
|
WO/2019/179928A1 |
Substituted succinimide-3-carboxamides, salts thereof and the use thereof as herbicidal agents. The invention relates to substituted succinimide-3-carboxamides of general formula (I) or the salts (I) thereof, wherein the groups in genera...
|
|
WO/2019/176875A1 |
The present invention is a heterobifunctional monodispersed polyethylene glycol represented by formula (1). (In the formula, each of X1 and Y1 represents an atomic group which contains a functional group that forms a covalent bond by rea...
|
|
WO/2019/176079A1 |
[Problem] To provide a biodegradable compound that has a structure degraded in cells, a lipid particle comprising the biodegradable compound and a medicinal composition containing the lipid particle. [Solution] According to one embodimen...
|
|
WO/2019/174533A1 |
A small molecule PD-1/PD-L1 inhibitor and the use thereof in drugs. Specifically, provided is a small molecule PD-1/PD-L1 inhibitor that is a chemical compound represented by formula (I), or a stereoisomer, geometric isomer, tautomer, ox...
|
|
WO/2019/175897A1 |
The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tau...
|
|
WO/2019/173182A1 |
The disclosure relates to compounds of Formula (II), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for ...
|
|
WO/2019/170115A1 |
Provided a pyrrolidineamide compound and a pharmaceutical composition containing this compound which can be used as a MAO-B inhibitor. Also provided methods of preparing this compound and pharmaceutical composition, and their use in the ...
|
|
WO/2019/173613A1 |
Disclosed are compounds, pharmaceutical compositions, and methods of treatment. The disclosed compounds are based on fused 1,4-diazepine and pyrrolidinedione scaffolds. The compounds may be utilized in pharmaceutical compositions and met...
|
|
WO/2019/166633A1 |
The present invention relates to compounds of formula (I) : (I) wherein Q is selected from O or S; R1 is an optionally substituted hydrocarbyl group which may optionally include one or more heteroatoms N, O or S in its carbon skeleton, p...
|
|
WO/2019/168357A1 |
Provided herein are water soluble salts of Formula I, wherein R1, A, and M are defined herein. Also provided herein are methods of preparing the salts of Formula I and methods of using the same.
|
|
WO/2019/168140A1 |
Provided are an amide compound represented by general formula [I] or a salt thereof, an agricultural and horticultural microbicide containing the amide compound or a salt thereof as an active ingredient, and a method of using the agricul...
|
|
WO/2019/167359A1 |
This compound is represented by formula (0). (In formula (0), RX denotes a 2nA-valent group having 1-70 carbon items or a single bond, the R1A moieties each independently denote: an optionally substituted alkyl group having 1-30 carbon a...
|
|
WO/2019/166615A1 |
A method of synthesising a compound of formula (I): (I) from a compound of formula (II): (II) where R8 is either: (i) Prot O3 ; or (ii) a group of formula (A1) in formula (I) and (A2) in formula (II): (A1), (A2).
|
|
WO/2019/169153A1 |
Disclosed are compounds of Formula (1), stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6,R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure a...
|
|
WO/2019/168866A1 |
Substituted cyclohexyl chemical entities of Formula (I): wherein Ra, G, and Rb have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods,...
|
|
WO/2019/165241A1 |
A method and composition for preventing, reducing, or treating steroid-induced ocular hypertension and steroid-induced glaucoma using a selective Grp94 inhibitor is presented. The Grp94-selective inhibitor can include methyl 2-(2-(1(4-br...
|
|
WO/2019/163917A1 |
Provided is a compound in which the balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor has been improved in order to develop a pharmaceutical useful for the treatment of S1P5-mediated diseases such as...
|
|
WO/2019/165200A1 |
A compound of Formula (I) or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt wherein the definitions of R1-R13 and L1-L4 are provided i...
|
|
WO/2019/164622A1 |
The disclosure is related to EMM-37 materials, processes of making, and uses of the same as well as structure directing agents useful for the preparation of the EMM-37 materials, processes and intermediates for making such structure dire...
|
